Brain monitoring in ICU via continuous pupillometry in closed eyes conditions

Cel

In this PoC we will validate Ocumind, a novel technology for closed-eye pupillometry in the neurological/neurosurgical ICU (neuroICU) and advance it toward commercialization. Assessment of pupil size and reactivity is central to evaluating neurologic injury, where pupillometry detects clinical deterioration such as brain herniation and elevated intracranial pressure (ICP), third-nerve palsy, seizures, and stroke. However, current bedside pupillometry is typically intermittent, qualitative, manual, and restricted to open-eye measurements, preventing continuous monitoring. A major unmet need is to provide real time alters on brain abnormalities based on non-invasive continuous pupil monitoring, a capability widely considered impossible until now. We recently developed a breakthrough technology combining short-wave infrared imaging with machine-learning algorithms to continuously monitor pupil size through closed eyelids in a contactless manner. In this PoC project we will first (Aim 1) compare closed-eye pupillometry to gold-standard clinical pupillometers that require eye opening. Next (Aim 2) we will deploy the system in the neuroICU alongside ICP and sedation monitoring to detect clinical abnormalities associated with pupil dynamics, generating validation data to attract investment. Finally (Aim 3) we will work with TAU’s technology transfer unit and business partners to expand the patent portfolio and bring the technology to market, either by establishing a start-up company or licensing the system to companies specializing in pupillometry and neuroICU monitoring. This technology can improve patient care, save lives, and reduce healthcare workload and costs. In the long term, a commercial system could be widely used beyond the neuroICU in diverse settings including ICU, surgical anesthesia (detecting arousal and intraoperative awareness, monitoring pain and analgesia), sleep medicine (detecting insomnia, nightmares, and nocturnal seizures), and beyond.